Immuneering (IMRX) announced a clinical supply agreement with Regeneron Pharmaceuticals (REGN) for its anti-PD-1 therapy, Libtayo. The supply agreement supports the evaluation of Immuneering’s lead product candidate, IMM-1-104, in combination with Libtayo in patients with unresectable or metastatic RAS-mutant non-small cell lung cancer, NSCLC, in Immuneering’s ongoing Phase 2a clinical trial of IMM-1-104 in advanced solid tumors. “We are excited to announce this collaboration, which is the first that Immuneering has entered with IMM-1-104. Regeneron is a global leader in cancer research and development, and the combination of IMM-1-104 and Libtayo in advanced non-small cell lung cancer has the potential to address unmet needs for patients with this disease,” said E.B. Brakewood, Chief Business Officer of Immuneering.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IMRX:
- Immuneering announces update from its Phase 2a arm studying IMM-1-104
- 3 Penny Stocks to Watch Now, 1/9/25
- Immuneering announce data update from Phase 2a trial of IMM-1-104
- Immuneering launches Pancreatic Cancer Advisory Board
- Immuneering to present data from Phase 2a trial of IMM-1-104 in early January